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Abstract 
Objectives: To present a new case of adverse cutaneous reaction during lithium treatment and to update the sys-
tematic review and meta-analysis of the incidence of this adverse reaction.
Methods: We conducted a systematic search (performed in September 2016) for peer-reviewed articles in English 
indexed in Medline (2011-present). Meta-analytical estimates were obtained using the “Metafor” package.
Case presentation: Ms. H., a 31-year-old Caucasian woman with BD1, was admitted to the inpatient unit for a 
full-blown psychotic episode and treated with carbamazepine 400 mg q.d., lithium carbonate 450 mg q.d., and 
risperidone 4 mg q.d. with clinical improvement. After 12 days from the start of psychopharmacological treatment, 
she manifested a cutaneous reaction that motivated the stop of carbamazepine treatment, as well as the increase in 
lithium carbonate dose (750 mg q.d.). Risperidone dose remained unvaried. Since the skin lesion persisted after 8 days 
from withdrawal of carbamazepine, the private practitioner stopped also lithium carbonate treatment (de-challenge), 
maintaining risperidone treatment. The cutaneous reaction resolved spontaneously after six days from withdrawal of 
lithium carbonate. Subsequently, the worsening of psychopathological conditions motivated a new admission dur-
ing which lithium carbonate was reintroduced (16 days after its suspension) (re-challenge). On the following day, we 
observed an itching erythematous maculopapular rash involving the trunk, the four limbs, and the oral mucosa.
Conclusions: Our case of an erythematous maculopapular rash during lithium treatment was the first to present a 
challenge–de-challenge–re-challenge sequence that suggests causality. Although meta-analysis does not point to an 
increased rate of adverse skin reaction during lithium treatment, clinicians should not neglect to monitor cutaneous 
symptoms during lithium treatment.
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Background
Lithium remains the mainstay for the treatment and 
prevention of mood episodes in bipolar disorder (BD) 
(Yatham et  al. 2013). Its prophylactic effectiveness has 
been demonstrated by naturalistic observational studies 
which showed that approximately one-third of lithium-
treated BD patients achieve full symptomatic remission 
(Garnham et al. 2007; Baldessarini and Tondo 2000), and 
that this pattern of clinical response remains stable in the 
long-term (Berghofer et al. 2013).
However, the effectiveness of lithium should be 
weighed against its side effect profile that might limit its 
acceptability by patients (McKnight et al. 2012). Indeed, 
it is well established that lithium treatment can impact 
kidney, thyroid, and parathyroid function (McKnight 
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et  al. 2012). A degree of uncertainty remains, however, 
on whether lithium, during short- and long-term treat-
ment, is associated with the manifestation of cutaneous 
adverse reactions. Although quantitative meta-analytical 
estimates did not show an increased rate of skin disor-
ders in lithium-treated patients compared to those given 
placebo (McKnight et al. 2012), there is substantial anec-
dotic evidence supporting this association. Indeed, some 
authors indicated that the rate of cutaneous adverse reac-
tions during lithium maintenance therapy might be as 
high as 45% (Jafferany 2008). Here, firstly we presented 
a new case of adverse cutaneous reaction during lithium 
treatment, confirmed by a re-challenge of the drug after 
its discontinuation. We then updated the study of McK-
night et al. (2012) which systematically reviewed and per-
formed data synthesis of pertinent literature published 
until 2010 (McKnight et al. 2012).
Case presentation
Ms. H., a 31-year-old Caucasian woman with BD1, was 
voluntarily admitted to the psychiatric ward of the San 
Martino Hospital of Oristano, Sardinia, Italy for a manic 
episode with mood-congruent psychotic features accord-
ing to the Diagnostic and Statistical Manual of Mental 
Disorders-5 (DSM-5) criteria.
The family history of Ms. H. was positive for mood 
disorders: her father was diagnosed with BD1 and her 
paternal grandmother with mood disorder not otherwise 
specified (NOS). Her premorbid personality had been 
characterized by cyclothymic temperament and rejection 
sensitivity. Her first illness episode presented at 21 years 
in concomitance with the end of a romantic relation-
ship. Specifically, she developed depressed mood, social 
withdrawal, and persecutory delusion for which she was 
treated with unspecified psychopharmacological treat-
ment. At the age of 24, during a euthymic phase, and in 
the absence of pharmacological treatment, she started 
presenting somatic symptoms (abdominal pain, change 
in bowel habits, and bloating) after a surgical operation 
for ovarian cyst removal. Around the same time, she 
experienced marked anxiety, ruminations, and social dis-
comfort with subsequent social withdrawal. Treatment 
with selective serotonin reuptake inhibitors (SSRI) was 
started with clinical remission.
Although in the following years the patient had a good 
social and work functioning, several residual psycho-
pathological symptoms remained, including mood fluc-
tuations, hypochondriac thoughts and behaviors, marked 
anxiety, and dietary restraint with weight loss aimed at 
facilitating control of bowel function. The absence of a 
complete clinical remission was partially due to the lack 
of compliance to clinical monitoring and psychophar-
macological treatment. The progressive increase in the 
severity of these psychopathological symptoms led to 
manifestation of a full-blown psychotic episode in early 
2016. This clinical picture motivated a 1-week admission 
at the end of March 2016 at the acute inpatient psychi-
atric unit in Pisa, Italy, where she was started on carba-
mazepine 400  mg q.d., lithium carbonate 450  mg q.d., 
and risperidone 4 mg q.d., which led to substantial clini-
cal improvement. Laboratory workup, including thyroid 
function parameters, was normal. After discharge from 
hospital, she moved to Sardinia and was seen by a pri-
vate practitioner for follow-up visits. After 12 days from 
the start of psychopharmacological treatment, she mani-
fested a cutaneous reaction that motivated the stop of 
carbamazepine treatment, as well as the increase in lith-
ium carbonate dose (750 mg q.d.) (challenge phase). Ris-
peridone dose remained unvaried. Since the skin lesion 
persisted after 8 days from withdrawal of carbamazepine, 
the private practitioner stopped also lithium carbon-
ate treatment (de-challenge), maintaining risperidone 
treatment. The cutaneous reaction resolved spontane-
ously after 6 days from withdrawal of lithium carbonate. 
On May 2016 after the manifestation of marked anxi-
ety, flight of ideas, pressured speech, decreased ability 
to concentrate, insomnia, and persecutory delusions, 
she came to our attention and was admitted at our unit 
where lithium carbonate was reintroduced (16 days after 
its suspension) (re-challenge). On the following day, we 
observed an itching erythematous maculopapular rash 
involving the trunk, the four limbs, and the oral mucosa. 
The dermatologist consultation indicated the presence 
of: “a drug-induced toxic reaction, characterized mor-
phologically by eruption of a large number of erythema-
tous macules of varying size, mostly with papules, which 
became confluent and itching. It is observable also a pal-
moplantar eruption of pale erythematous macular lesions 
with scarlatiniform characteristics”. Lithium carbon-
ate was immediately stopped with resolution of the skin 
lesion on the subsequent day. This severe adverse reac-
tion was described and sent to the Sardinian Regional 
Centre of Pharmacovigilance. Their assessment with the 
Naranjo algorithm (Naranjo et  al. 1981) classified the 
relationship between the cutaneous adverse reaction and 
the use of lithium as “probable.”
Systematic review and meta‑analysis
To update the study of McKnight et  al. (2012), we con-
ducted a systematic search (performed in September 
2016) for peer-reviewed articles in English indexed in 
Medline (2011-present). The terms used for the elec-
tronic database search were: lithium AND (skin OR 
dermatology OR cutaneous side effects OR psoriasis 
OR rash OR Stevens-Johnson syndrome). Studies were 
included if they reported on adverse cutaneous reaction 
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during lithium treatment. Data on cutaneous adverse 
reactions in published or unpublished randomized 
clinical trials (RCTs) since 2011, comparing lithium (as 
monotherapy or add-on) with placebo or other pharma-
cological treatments, were extracted from ClinicalTrials.
gov, which is a database of publicly and privately sup-
ported clinical studies of human participants conducted 
around the world (www.ClinicalTrials.gov). Meta-analyt-
ical estimates were obtained using the “Metafor” package 
(Viechtbauer 2010). Since adverse cutaneous reactions in 
the included clinical trials comparing lithium with pla-
cebo were very rare, we used the Peto odds ratio (OR) 
fixed-effect method.
Our systematic search found 93 studies indexed in 
Medline. We also found 28 clinical trials including one 
previous study examined in the meta-analysis of McK-
night et  al. (2012). The review process is summarized 
in Fig.  1 according to the preferred reporting items 
Fig. 1 Preferred reporting items for systematic reviews and meta-analyses (PRISMA) tree
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for systematic reviews and meta-analyses (PRISMA) 
(Moher et al. 2009). Five of the studies indexed in Med-
line met inclusion criteria for the qualitative synthesis: 
four were case reports and one was an observational 
case/control study (Table  1). The four case reports 
presented a varying spectrum of skin disorders asso-
ciated with lithium treatment. Specifically, Maejima 
et  al. (2012) reported on a 55-year-old male affected 
by psychosis who developed psoriasis verrucosa, a rare 
and atypical form of psoriasis. Although the patient 
improved after treatment with adalimumab, a tumor 
necrosis factor-alpha (TNF-α) inhibitor, it was not 
specified whether an attempt was made to discontinue 
lithium in order to observe a decrease in the severity of 
the lesions.
The case described by Wang and Yang (2013) con-
cerned a 37-year-old BD1 woman who presented a non-
itching, erythematous, maculopapular rash after the 
start of therapy with lithium 900 mg q.d. which resolved 
spontaneously after its discontinuation. Further, Scarfi 
and Arunachalam (2013) reported on the manifestation 
of facial acne in a 40-year-old woman after 4 months of 
treatment. Again, the skin lesion completely resolved 
after treatment discontinuation. Finally, Bugueno et  al. 
(2013) described the onset of an oral lichenoid mucosal 
lesion in concomitance with the initiation of the treat-
ment in a 25-year-old BD female patient. Complete 
resolution of the skin lesion was observed after discon-
tinuation of lithium. The large observational case-control 
study by Spoendlin et al. (2014) interestingly found that 
lithium treatment was associated with a decreased risk of 
rosacea.
Data on cutaneous adverse reactions were extracted for 
meta-analysis from three clinical trials: Goodwin et  al. 
(2004), Geller et al. (2012), and NTC01189812 (Table 2). 
The first study was also included in the meta-analysis 
of McKnight et  al. (2012). Meta-analysis did not show 
a significant difference in the rate of cutaneous adverse 
reaction between lithium- and placebo-treated patients 
(Peto OR 1.14, 95% [Confidence Interval (CI) 0.44–2.94], 
P =  0.78; heterogeneity Q =  0.92, P =  0.34), as well as 
between those treated with lithium or with other treat-
ments (OR 0.61, [95% CI 0.34–1.11], P = 0.11; heteroge-
neity Q = 0.91, P = 0.63).
Discussion and conclusion
We presented a case of a diffuse erythematous maculo-
papular rash during lithium treatment in a 31-year-old 
woman with BD1. This observation adds to the limited 
anecdotal literature on adverse cutaneous reaction dur-
ing lithium treatment. The manifestation of the lesion 
appeared similar to that described in previous reports 
(Swartz and Holkesvick 1981; Wang and Yang 2013). 
However, differently from most of previously published 
reports, our clinical case strongly suggests causality 
between the use of lithium and the onset of the skin reac-
tion, particularly in light of the reoccurrence of the mac-
ulopapular rash following drug re-challenge.
Table 1 Cutaneous adverse reactions during lithium treatment: case reports and observational studies
BD bipolar disorder, BD1 bipolar disorder type 1, NA: not available, C–D–R challenge–de-challenge–re-challenge, C–D challenge–de-challenge
Study
Case reports Number 
of patients






Maejima et al. 
(2012)
1 Male 55 Psychosis NA Psoriasis NA None
Wang and Yang 
(2013)
1 Female 37 BD1 7 days Non-itching, 
erythematous, 
maculopapular 
rash over 70% 






1 Female 40 BD 4 months Facial acne C–D None
Bugueno et al. 
(2013)
1 Female 25 BD 1 month Oral lichenoid 
lesion

















>180 days 53,927 Incidence of 
rosacea
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One could argue that the use of carbamazepine could 
be related to the manifestation of the skin reaction. 
However, the maculopapular rash persisted 8  days after 
discontinuation of carbamazepine and it is unlikely 
that the drug might have remained in the bloodstream 
for such a time given that its half-life should have been 
around 10–20  h after 8  weeks of treatment (Bertilsson 
1978). Further, cross-reactivity, which is common for 
adverse skin reactions with carbamazepine and chemi-
cally related drugs, should be excluded since lithium does 
not have any similarity with the aromatic structure of 
carbamazepine.
One final comment is needed on the findings of our 
meta-analysis. We confirmed that the evidence so far 
available does not point to an association between lith-
ium treatment and cutaneous adverse reaction. These 
findings should be reconciled, however, with the recur-
rent manifestation of these events in lithium-treated 
patients. One possible explanation is that the incidence 
rate of these events is quite heterogeneous, with esti-
mates ranging from 3.4 to 45% (Jafferany 2008). There-
fore, the probability of observing an adverse cutaneous 
reaction during lithium treatment depends on the design 
of the clinical trial (duration of follow-up, inclusion cri-
teria, method of assessment of adverse reactions) as well 
as on the characteristics of the patients included (type of 
diagnosis, presence and duration of lithium treatment 
before the start of the clinical trial, pre-existing allergic 
diathesis, history of psoriasis). It is conceivable that large 
registry study might be more suitable to the task of quan-
tifying the incidence of this adverse reaction of lithium.
In conclusion, we presented a case of an erythematous 
maculopapular rash during lithium treatment. Although 
this type of skin reaction has been reported previously 
in the literature, our case is the first to present a chal-
lenge–de-challenge–re-challenge sequence that suggests 
causality. Although meta-analysis does not point to an 
increased rate of adverse skin reaction during lithium 
treatment, clinicians should not neglect to monitor cuta-
neous symptoms, particularly in BD patients at high risk, 
such as those with an allergic diathesis.
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Table 2 Cutaneous adverse reactions during lithium treatment: randomized clinical trials
NA not available, BD bipolar disorder, BD1 bipolar disorder type 1, MDD major depressive disorder, DNOS depression not otherwise specified, BPD borderline 
personality disorder
Study Number of patients Diagnosis Duration of lithium 
treatment
Outcome measured Follow-up Results
Goodwin et al. (2004) 167 (166 completed) 
lithium
280 (227 completed) 
lamotrigine
191 (190 completed) 
placebo
BD1 NA Self-reported 
incidence of new-





Geller et al. (2012) 89 risperidone
90 (84 completed) 
lithium
100 (97 completed) 
valproic acid
BD1 NA Systematic structured 
assessment of side 
effects
8 weeks Lithium: 6%
Risperidone: 6.7%
Valproic acid: 13.4%
NCT01189812 40 citalopram + pla-
cebo




4 weeks Self-reported 
incidence of new-
onset skin disorders 
during treatment
4 weeks Citalopram + lithium: 
2.5%
Citalopram + placebo: 
2.5%
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